RedHill Biopharma (RDHL) Tops Q4 EPS Views

RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).

EPS in Q413 was 0.05.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Innovaro (INV) Misses Q2 EPS by 9c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c